TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

Eine Analyse von InvestingPro zeigt, dass das Unternehmen mit einem gesunden Verhältnis von kurzfristigen Vermögenswerten zu kurzfristigen Verbindlichkeiten von 2,41 eine starke Fähigkeit zur ...

Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

Das GeneDx-Management bestätigte, dass das Unternehmen kein "Code Stacking" betreibt und angemessene CPT-Codes für Genom- und Exom-Tests abrechnet, die das Kerngeschäft darstellen. Die Analysten hoben ...

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...

GeneDx has made "important" product improvements to its rapid whole-genome sequencing (rWGS) product in 2024 that should help it unlock genomic testing in the neonatal intensive care unit setting, CEO ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...